Kiran Zaveri, MD
Internal Medicine · Metairie, LANPI 1558344234
Payments from drug & device makers
Across 337 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$708
- Novo Nordisk$699
- AstraZeneca$472
- GSK$391
- Johnson & Johnson$317
- Sanofi-aventis U.S. LLC$221
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,90699%
- Education$251%
- Gifts$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 53 | $708 |
| Novo Nordisk | 73 | $699 |
| AstraZeneca | 26 | $472 |
| GSK | 21 | $391 |
| Johnson & Johnson | 24 | $317 |
| Sanofi-aventis U.S. LLC | 14 | $221 |
| Amgen | 13 | $219 |
| Lilly USA, LLC | 13 | $215 |
| Boehringer Ingelheim | 12 | $192 |
| Novartis | 11 | $166 |
| Merck | 10 | $145 |
| Esperion Therapeutics, Inc. | 8 | $139 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $131 |
| Bayer | 6 | $120 |
| Sumitomo Pharma America, Inc. | 5 | $101 |
| Pfizer | 5 | $92 |
| Astellas Pharma US Inc | 5 | $81 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Ironwood Pharmaceuticals, Inc | 3 | $54 |
| Abbott | 2 | $44 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Radius Health, Inc. | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Biogen | 1 | $24 |
| IBSA Pharma Inc. | 1 | $23 |
| Seqirus USA Inc | 1 | $23 |
| Mylan Specialty L.p. | 1 | $22 |
| Ascend Therapeutics US, LLC | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Circassia Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
How this compares
$4,949 in reported general payments places this provider in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 301 | $354,023 |
| XareltoRivaroxaban | 101 | $125,896 |
| MounjaroTirzepatide | 94 | $124,475 |
| OzempicSemaglutide | 71 | $92,498 |
| ProliaDenosumab | 46 | $79,837 |
| FarxigaDapagliflozin Propanediol | 65 | $77,914 |
| JardianceEmpagliflozin | 40 | $54,586 |
| JanuviaSitagliptin Phosphate | 37 | $52,562 |
| MyrbetriqMirabegron | 45 | $36,051 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $32,845 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $26,335 |
| Repatha SureclickEvolocumab | 15 | $21,010 |
| EntrestoSacubitril/Valsartan | 13 | $18,958 |
| CreonLipase/Protease/Amylase | 11 | $16,695 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $14,939 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $92 | $354,023301 claims |
| Lilly USA, LLCMounjaro, Trulicity | $215 | $138,777105 claims |
| Johnson & JohnsonXarelto | $317 | $125,896101 claims |
| AstraZenecaFarxiga, Symbicort | $472 | $92,85396 claims |
| Novo NordiskOzempic | $699 | $92,49871 claims |
| AmgenProlia | $219 | $79,83746 claims |
| Boehringer IngelheimJardiance | $192 | $54,58640 claims |
| MerckJanuvia | $145 | $52,56237 claims |
| AbbVieCreon, Linzess, Synthroid | $708 | $36,17997 claims |
| Astellas Pharma US IncMyrbetriq | $81 | $36,05145 claims |
| GSKTrelegy Ellipta | $391 | $32,84542 claims |
| NovartisEntresto | $166 | $18,95813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Metairie
- Robert JeanfreauMetairie$13.4M
- Frederick DantagnanMetairie$421K
- William SmithNew Orleans$50.5M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
- Satinder SainiCrowley$1.8M
- Randall MillerEunice$1.2M
- Donna RyanBaton Rouge$991K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.